Understanding Diabetic Foot Ulcers
Diabetic foot ulcers are one of the most serious complications of diabetes. These chronic wounds can be difficult to heal because diabetes may affect circulation, nerve function, immune response, and the body’s natural repair process.
When wounds remain open for long periods of time, they can increase the risk of infection, hospitalization, and more serious complications. Standard care often includes wound cleaning, debridement, infection control, offloading pressure from the foot, and specialized dressings. While these treatments are important, some ulcers remain slow to heal. Because of this, researchers are exploring regenerative approaches that may help support the biological processes involved in wound repair.
Why Researchers Are Studying WJ-MSC-Derived Exosomes
Wharton’s Jelly is a tissue found in the umbilical cord and is a rich source of mesenchymal stem cells, or MSCs. These cells are known for releasing signaling molecules that may influence inflammation, blood vessel formation, tissue repair, and immune activity.
Exosomes are tiny extracellular vesicles released by cells. Instead of acting like whole cells, exosomes work more like messengers. They carry proteins, lipids, and genetic material that can communicate with nearby cells and help guide tissue responses.
For diabetic foot ulcers, WJ-MSC-derived exosomes are being studied because they may help support several stages of wound healing, including:
- Reducing chronic inflammation
- Supporting new blood vessel formation
- Encouraging skin cell movement and repair
- Helping regulate immune activity
- Supporting extracellular matrix remodeling
Study Overview
In this 2025 randomized controlled clinical trial, researchers studied whether Wharton’s Jelly MSC-derived exosome gel could improve healing in patients with persistent diabetic foot ulcers.
The study included 110 participants with diabetic foot ulcers. Participants were divided into three groups:
- A treatment group receiving standard of care plus WJ-MSC-derived exosome gel
- A control group receiving standard of care alone
- A placebo group receiving standard of care plus a similar vehicle gel
The exosome gel was applied topically during the treatment period, and patients were followed over time to evaluate wound size, healing progress, complete epithelialization, and safety.
All groups received standard wound care, including debridement, saline cleansing, sterile gauze, non-compressive bandaging, and instructions for daily wound cleaning and redressing.
Key Findings
The results were encouraging for the group treated with WJ-MSC-derived exosome gel.
By the end of the study, 53 patients, or 62%, had achieved complete healing. The treatment group had a significantly higher percentage of complete healing compared with the control group. The study also found that the average time to complete healing was shorter in the treated group. Patients receiving WJ-MSC-derived exosome gel had a mean healing time of 6 weeks, compared with 20 weeks in the control group.
The treated group also showed a meaningful reduction in ulcer area early in the study. According to the authors, the median ulcer surface area in the treatment group decreased from 6 cm² at baseline to 4 cm² after 2 weeks and 2.7 cm² after 4 weeks.
Importantly, the study also evaluated safety and tolerability. The researchers monitored adverse events and clinical outcomes throughout the trial, and the findings supported the potential safety of the topical exosome gel approach within the study setting.
How WJ-MSC-Derived Exosomes May Support Wound Healing
Diabetic foot ulcers are complex because several biological problems can happen at the same time. Poor circulation, inflammation, nerve damage, infection risk, oxidative stress, and impaired tissue repair can all slow healing. WJ-MSC-derived exosomes may support wound healing by helping regulate several of these processes at once.
One important mechanism is inflammation control. Chronic inflammation can keep a wound stuck in an early healing phase, preventing normal tissue repair. MSC-derived exosomes may help shift immune activity toward a more balanced, repair-supportive response.
Another key mechanism is angiogenesis, or the formation of new blood vessels. Blood vessels deliver oxygen, nutrients, and repair signals to damaged tissue. The study discusses how MSC-exosomes may support vascular regeneration through growth factors and signaling pathways involved in new vessel formation.
Exosomes may also help support skin cell activity. During wound healing, cells such as keratinocytes need to move, multiply, and help rebuild the skin barrier. WJ-MSC-derived exosomes may carry signals that encourage these repair processes.
Together, these effects may help create a wound environment that is more supportive of tissue closure and long-term repair.
Why This Research Matters
This study is meaningful because it focuses on a real clinical problem that affects many people with diabetes. Diabetic foot ulcers are often challenging to manage, and delayed healing can have major effects on quality of life.
The research also highlights the growing interest in cell-free regenerative medicine. Instead of applying whole stem cells, this approach uses exosomes derived from Wharton’s Jelly MSCs. This may offer a way to study the signaling benefits of MSCs while focusing on a topical, targeted wound-care strategy.
For chronic wound research, the findings suggest that WJ-MSC-derived exosomes may help support faster wound closure when used alongside standard care.
Limitations and Future Directions
Although the findings are promising, more research is still needed. The authors noted the need for larger clinical trials to confirm safety, effectiveness, standard dosing, and the best methods for clinical application.
Future studies may also help clarify which patients are most likely to benefit, how long results last, and how WJ-MSC-derived exosomes compare with other advanced wound-care approaches.
Conclusion
This clinical study provides encouraging evidence that Wharton’s Jelly MSC-derived exosomes may support healing in diabetic foot ulcers. When used with standard wound care, the exosome gel was associated with improved wound closure and a shorter average time to complete healing compared with standard care alone.
While additional research is needed, these findings highlight the potential of WJ-MSC-derived exosomes as a promising regenerative approach for chronic wound healing. By supporting inflammation control, angiogenesis, immune regulation, and tissue repair, exosome-based therapies may play an important role in the future of diabetic wound care.
Source
Kishta MS, Hafez AM, Hydara T, Hamed Z, Bahr MM, Shamaa AA, Abdallah AN. The transforming role of Wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Research & Therapy. 2025 Oct 13;16:559. doi: 10.1186/s13287-025-04690-y. PMID: 41084065; PMCID: PMC12519741. Available from: https://link.springer.com/article/10.1186/s13287-025-04690-y
Related Treatment Pages